Evolus Share Price (NASDAQ: EOLS)

$7.63

▲

0.11

(1.46%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Evolus Stock chart to analyse performance

Evolus stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$7.48
Today's High:$7.63
$7.63
1.97%
Downside
Day's Volatility :1.97%
Upside
0.0%
52 Weeks Low:$5.71
52 Weeks High:$17.82
$7.63
25.16%
Downside
52 Weeks Volatility :67.96%
Upside
57.18%

Evolus Stock Returns

Period	Evolus, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-23.47%	3.6%	0.0%
6 Months	-46.79%	-7.7%	0.0%
1 Year	-51.03%	-12.6%	0.0%
3 Years	-16.52%	9.5%	-4.7%

Evolus, Inc. Key Stats

Check Evolus key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$7.52
Open	$7.51
Today's High	$7.63
Today's Low	$7.48
Market Capitalization	$493.5M
Today's Volume	$472.1K
52 Week High	$17.82
52 Week Low	$5.71
Revenue TTM	$277.9M
EBITDA	$-35.2M
Earnings Per Share (EPS)	$-0.97
Profit Margin	-22.31%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-18729.61%

Stock Returns calculator for Evolus Stock including INR - Dollar returns

The Evolus stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Evolus investment value today

Current value as on today

₹53,302

Returns

₹46,698

(-46.7%)

Returns from Evolus Stock

₹51,982 (-51.98%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Evolus Stock

138%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Evolus Stock from India on INDmoney has increased by 138% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Evolus, Inc.

Name
Holdings %
Name
Holdings %
TANG CAPITAL MANAGEMENT LLC
7.73%
BlackRock Inc
6.69%
Nantahala Capital Management, LLC
6.49%
Caligan Partners LP
5.17%
Vanguard Group Inc
5.13%
Perceptive Advisors LLC
3.83%

Analyst Recommendation on Evolus Stock

Rating

Trend

Buy

92%Buy

7%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Evolus(by analysts ranked 0 to 5 stars)

Evolus Share Price Target

What analysts predicted

Upside of 149.02%

Target:

$19.00

Current:

$7.63

Evolus share price target is $19.00, a slight Upside of 149.02% compared to current price of $7.63 as per analysts' prediction.

Evolus Stock Insights

Price Movement
In the last 6 months, EOLS stock has moved down by -47.7%
Increasing Revenue
Revenue is up for the last 2 quarters, 68.07M → 69.38M (in $), with an average increase of 1.9% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -18.89M → -17.14M (in $), with an average increase of 10.2% per quarter
EOLS vs NBIX (1 yr)
In the last 1 year, Neurocrine Biosciences Inc. has given 9.9% return, outperforming this stock by 61.9%
EOLS vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 35.1% return, outperforming this stock by 60.7%
Price to Sales
ForEOLS every $1 of sales, investors are willing to pay $1.7, whereas for Neurocrine Biosciences Inc., the investors are paying $5.6 for every $1 of sales.

Evolus, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$34.9M	-
Net Income	$-90.0M	↑ 92.11%
Net Profit Margin	-257.79%	-

	FY20	Y/Y Change
Revenue	$56.5M	↑ 61.89%
Net Income	$-163.0M	↑ 81.06%
Net Profit Margin	-288.31%	↓ 30.52%

	FY21	Y/Y Change
Revenue	$99.7M	↑ 76.29%
Net Income	$-46.8M	↓ 71.28%
Net Profit Margin	-46.96%	↑ 241.35%

	FY22	Y/Y Change
Revenue	$148.6M	↑ 49.1%
Net Income	$-74.4M	↑ 58.97%
Net Profit Margin	-50.07%	↓ 3.11%

	FY23	Y/Y Change
Revenue	$202.1M	↑ 35.98%
Net Income	$-61.7M	↓ 17.1%
Net Profit Margin	-30.52%	↑ 19.55%

	FY24	Y/Y Change
Revenue	$266.3M	↑ 31.76%
Net Income	$-50.4M	↓ 18.26%
Net Profit Margin	-18.94%	↑ 11.58%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$59.3M	↓ 2.73%
Net Income	$-13.1M	↑ 10.8%
Net Profit Margin	-22.09%	↓ 2.69%

	Q2 FY24	Q/Q Change
Revenue	$66.9M	↑ 12.77%
Net Income	$-11.4M	↓ 13.42%
Net Profit Margin	-16.96%	↑ 5.13%

	Q3 FY24	Q/Q Change
Revenue	$61.1M	↓ 8.7%
Net Income	$-19.2M	↑ 68.9%
Net Profit Margin	-31.38%	↓ 14.42%

	Q4 FY24	Q/Q Change
Revenue	$78.9M	↑ 29.24%
Net Income	$-6.8M	↓ 64.57%
Net Profit Margin	-8.6%	↑ 22.78%

	Q1 FY25	Q/Q Change
Revenue	$68.1M	↓ 13.77%
Net Income	$-18.9M	↑ 178.19%
Net Profit Margin	-27.75%	↓ 19.15%

	Q2 FY25	Q/Q Change
Revenue	$69.4M	↑ 1.93%
Net Income	$-17.1M	↓ 9.26%
Net Profit Margin	-24.7%	↑ 3.05%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$26.9M	-

	FY20	Y/Y Change
Profit	$38.2M	↑ 42.1%

	FY21	Y/Y Change
Profit	$56.1M	↑ 46.8%

	FY22	Y/Y Change
Profit	$92.7M	↑ 65.18%

	FY23	Y/Y Change
Profit	$140.5M	↑ 51.54%

	FY24	Y/Y Change
Profit	$182.3M	↑ 29.73%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$39.9M	↓ 1.24%

	Q2 FY24	Q/Q Change
Profit	$46.4M	↑ 16.43%

	Q3 FY24	Q/Q Change
Profit	$42.9M	↓ 7.63%

	Q4 FY24	Q/Q Change
Profit	$50.3M	↑ 17.46%

	Q1 FY25	Q/Q Change
Profit	$46.7M	↓ 7.33%

	Q2 FY25	Q/Q Change
Profit	$45.3M	↓ 2.86%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-93.4M	↑ 263.83%
Investing Cash Flow	$-23.4M	↑ 260277.78%
Financing Cash Flow	$133.5M	↑ 12.38%

	FY20	Y/Y Change
Operating Cash Flow	$-57.9M	↓ 38.03%
Investing Cash Flow	$12.2M	↓ 152.04%
Financing Cash Flow	$38.3M	↓ 71.29%

	FY21	Y/Y Change
Operating Cash Flow	$-33.4M	↓ 42.31%
Investing Cash Flow	$4.0M	↓ 66.95%
Financing Cash Flow	$73.1M	↑ 90.5%

	FY22	Y/Y Change
Operating Cash Flow	$-8.8M	↓ 73.72%
Investing Cash Flow	$-1.4M	↓ 134.52%
Financing Cash Flow	$-1.5M	↓ 102.08%

	FY23	Y/Y Change
Operating Cash Flow	$-34.0M	↑ 287.6%
Investing Cash Flow	$-1.6M	↑ 16.97%
Financing Cash Flow	$44.6M	↓ 3044.66%

	FY24	Y/Y Change
Operating Cash Flow	$-18.0M	↓ 47.07%
Investing Cash Flow	$-4.8M	↑ 196.44%
Financing Cash Flow	$47.4M	↑ 6.21%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-10.6M	↓ 1405.66%
Investing Cash Flow	$-797.0K	↑ 120.78%
Financing Cash Flow	$45.7M	↑ 94.12%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-6.5M	↓ 39.05%
Investing Cash Flow	$-1.3M	↑ 57.34%
Financing Cash Flow	$4.5M	↓ 90.19%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-5.7M	↓ 11.56%
Investing Cash Flow	$-1.4M	↑ 12.44%
Financing Cash Flow	$-1.4M	↓ 131.6%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$4.8M	↓ 184.03%
Investing Cash Flow	$-1.4M	↓ 3.4%
Financing Cash Flow	$-1.3M	↓ 7.27%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-15.6M	↓ 425.12%
Investing Cash Flow	$-1.9M	↑ 36.64%
Financing Cash Flow	$-1.6M	↑ 24.22%

Evolus Technicals Summary

Sell

Neutral

Buy

Evolus is currently in a neutral trading position according to technical analysis indicators.

Evolus, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Evolus, Inc.	-16.61%	-46.79%	-51.03%	-16.52%	90.75%
Haleon Plc Spon Ads	1.5%	-7.33%	-3.49%	69.05%	32.32%
United Therapeutics Corporation	3.57%	-1.69%	-13.51%	34.83%	71.41%
Zoetis Inc.	6.13%	-8.28%	-14.8%	-1.88%	-3.48%
Neurocrine Biosciences Inc.	8.29%	21.94%	11.59%	32.16%	20.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Evolus, Inc.	NA	NA	NA	-0.55	-187.3	-0.11	NA	-0.29
Haleon Plc Spon Ads	21.53	21.53	3.14	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.9	11.9	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.97	26.97	2.53	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	41.3	41.3	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Evolus, Inc.	Buy	$493.5M	90.75%	NA	-22.31%
Haleon Plc Spon Ads	Buy	$43.4B	32.32%	21.53	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.41%	11.9	40.36%
Zoetis Inc.	Buy	$69.3B	-3.48%	26.97	27.83%
Neurocrine Biosciences Inc.	Buy	$13.8B	20.59%	41.3	13.88%

About Evolus, Inc.

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Organization	Evolus
Employees	394
CEO	Mr. David Moatazedi
Industry	Health Technology

Key Management of Evolus, Inc.

Name	Title
Mr. David Moatazedi	President, CEO & Director
Ms. Tomoko Yamagishi-Dressler	Chief Marketing Officer
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D.	Chief Medical Officer and Head of Research & Development
Mr. Nareg Sagherian	Head of Global Investor Relations & Corporate Communications
Mr. Jeffrey J. Plumer	General Counsel
Mr. Kurt Knab	Senior Vice President of Sales
Ms. Jessica Novak	Senior Vice President of Human Resources

Important FAQs about investing in EOLS Stock from India :

What is Evolus share price today?

Evolus share price today is $7.63 as on August 30, 2025 at 1:29 am IST at the close of the market. Evolus share today touched a day high of $7.63 and a low of $7.48.

What is the 52 week high and 52 week low for Evolus share?

Evolus share touched a 52 week high of $17.82 and a 52 week low of $5.71. Evolus stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $7.63, lower by 57.18% versus the 52 week high.

How to invest in Evolus Stock (EOLS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Evolus on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Evolus Shares that will get you 0.1966 shares as per Evolus share price of $7.63 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Evolus Stock (EOLS) from India?

Indian investors can start investing in Evolus (EOLS) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Evolus stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Evolus share’s latest price of $7.63 as on August 30, 2025 at 1:29 am IST, you will get 1.3106 shares of Evolus. Learn more about fractional shares .

What are the returns that Evolus has given to Indian investors in the last 5 years?

Evolus stock has given 90.75% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?